Boehringer Ingelheim, with major CT presence, announces plans to invest $10B in U.S.

Hartford Business Journal – Monday, December 22, 2025
By Greg Bordonaro

Boehringer Ingelheim, one of Connecticut’s largest pharmaceutical employers, has reached an agreement with the U.S. government that includes commitments to lower the cost of some medicines for American patients and expand the company’s U.S. operations.

The privately held, Germany-based drugmaker operates its U.S. headquarters in Ridgefield and maintains a significant research, manufacturing and administrative presence in Connecticut. The agreement places the company among a group of major pharmaceutical firms negotiating voluntary pricing and investment arrangements with the federal government.

As part of the deal, Boehringer Ingelheim agreed to participate in a federal initiative aimed at offering discounted prescription drugs directly to consumers and to align certain pricing practices with administration policies. In return, the company would be exempt from potential tariffs tied to national security trade provisions, according to summaries released by the company and federal officials.

Boehringer Ingelheim also said it plans to invest about $10 billion in the United States through 2028 to expand pharmaceutical research, development and manufacturing, including roughly $1 billion in capital spending. The company did not specify how much of that investment would be directed to Connecticut or whether it would lead to new jobs in the state.

The company employs thousands of workers nationwide and has long been a major player in Connecticut’s life sciences sector, with operations that include drug development, manufacturing and corporate functions.

The agreement is part of a broader federal effort to reduce prescription drug costs while encouraging drugmakers to increase domestic production and investment. Similar arrangements have been announced with other pharmaceutical companies in recent weeks.

Some consumer advocates have raised questions about whether the voluntary agreements will translate into meaningful reductions in out-of-pocket costs for patients, citing limited detail on which drugs will be affected and how pricing changes will be implemented.

Access this article at its original source.